The OoC systems offer the complexity of tissues and the simplicity of cell culture endpoints. Defined systems with vasculature-like perfusion are biologically characterized to cover key mechanisms of drug efficacy and safety, in a fit-for-purpose perspective. We develop studies to test small molecules, immunotherapies, RNA-targeting therapies and gene therapies safety and/or efficacy. Small molecule testing is focused on toxicology endpoints with advanced live imaging tools. Biological drugs covering immunotherapy cover on and off target effects that depend on the immune system activation and cell recruitment. RNA-targeting therapies studies cover target related toxicological responses. Gene therapy studies focus on supporting drug discovery and selection of the most effective therapies for human tissues. We focus the pharma applications on the Retina-on-a-chip model, Heart-on-a-chip, Choroid-on-a-chip and White-adipose tissue chip and apply toxicological endpoints and tissue specific assays to evaluate drug effects dynamically and over long term studies.

Funding: Industry partners;

Publications

J. Rogal*, K. Schlünder*, P. Loskill
Developer’s Guide to an Organ-on-Chip Model
ACS Biomater. Sci. Eng., 2022, 8, 4643-4647, https://doi.org/10.1021/acsbiomaterials.1c01536

P. Loskill, R. Hardwick, A. Roth
Challenging the pipeline
Stem Cell Rep., 2021, 16, 2033-2037, https://doi.org/10.1016/j.stemcr.2021.08.004

K. Achberger*, M. Cipriano*, M. Düchs*, C. Schön*, S. Michelfelder, B. Stierstorfer, T. Lamla, S.G. Kauschke, J. Chuchuy, J. Roosz, L. Mesch, V. Cora, S. Pars, N. Pashkovskaia, S. Corti, S.-M. Hartmann, A. Kleger, S. Kreuz, U. Maier, S. Liebau, P. Loskill
Human stem cell-based retina-on-chip as new translational model for validation of AAV retinal gene therapy vectors
Stem Cell Rep., 2021, 16, 2242-2256, https://doi.org/10.1016/j.stemcr.2021.08.008

I.T. Maulana, E. Kromidas, L. Wallstabe, M. Cipriano, M. Alb, C. Zaupa, M. Hudescek, B. Fogal, P. Loskill
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Adv. Drug. Deliv. Rev., 2021, 173, 281-305, https://doi.org/10.1016/j.addr.2021.03.015

N. Franzen, W. van Harten, V. Retel, P. Loskill, A.J.M van den Eijnden-van-Raaij, M. IJzerman
Impact of organ-on-a-chip technology on pharmaceutical R&D costs
Drug Discov. Today, 2019, 24, 1720-1724, https://doi.org/10.1016/j.drudis.2019.06.003

P. Loskill, J. Wu
Stem cell based human organ-on-a-chip models for drug discovery and development
Adv. Drug. Deliv. Rev., 2019, 140, 1-2, https://doi.org/10.1016/j.addr.2019.07.004

J.C. Haderspeck*, J. Chuchuy*, S. Kustermann, S. Liebau, P. Loskill
Organ-on-a-Chip technologies that can transform ophthalmic drug discovery and disease modelling
Expert Opin. Drug Discov., 2019, 14, 47-57, https://doi.org/10.1080/17460441.2019.1551873